Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis
Launched by UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL · Sep 29, 2017
Trial Information
Current as of July 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • UF rate \>10 mL/h/kg in \>30% of treatments in a 30-day screening period (require ≥6 outpatient HD treatments in this period)
- • Age 18-85 years
- • Ability to converse comfortably in English or Spanish
- • Receipt of in-center maintenance HD at Carolina Dialysis clinics in Carrboro or Siler City, North Carolina
- • ≥90 days on HD
- • Free of bloodstream infection during screening period
- • Willingness to undergo all study testing
- • Evidence of a signed and dated informed consent document
- Exclusion Criteria:
- • Systolic BP unable to be measured by arm cuff
- • \>1 hospitalization during screening period
- • Unstable angina per treating nephrologist
- • End-stage cirrhosis per treating nephrologist
- • New York Heart Association class IV heart failure per treating nephrologist
- • Pregnant
- • More than 4 times per week HD
- • Incarcerated
- • Anticipated kidney transplant within 6 months per treating nephrologist
- • Non-adherence to HD prescription (\>2 unexplained absences during screening period)
- • Sodium profiling or UF profiling in standard HD prescription
- • Decisionally challenged, unable to provide informed consent
About University Of North Carolina, Chapel Hill
The University of North Carolina at Chapel Hill (UNC) is a leading research institution renowned for its commitment to advancing health and science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, UNC conducts cutting-edge research across various fields, including medicine, public health, and biomedical sciences. The university is dedicated to improving patient care and health outcomes by translating its research findings into practical applications. UNC’s clinical trials are designed to evaluate new therapies, interventions, and technologies, ensuring that they meet the highest ethical and scientific standards while fostering a culture of inclusivity and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Carrboro, North Carolina, United States
Siler City, North Carolina, United States
Patients applied
Trial Officials
Jennifer Flythe, MD, MPH
Principal Investigator
University of North Carolina, Chapel Hill
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials